Epigral Q2 FY27 PAT Jumps 26% YoY to ₹64 Cr

Epigral Limited announced its un-audited financial results for the quarter ended September 30, 2026 (Q2 FY27). The company reported a 26% year-on-year growth in Profit After Tax (PAT), reaching ₹64 Crore, compared to ₹51 Crore in Q2 FY26. Quarterly revenue increased by 28% to ₹752 Crore from ₹589 Crore in the same period last fiscal. Sales volume grew by 6% despite challenging market conditions. The Derivatives & Specialty business contributed 57% of revenue. EBITDA stood at ₹136 Crore, with an EBITDA margin of 18% impacted by high raw material costs. For the first half of FY27 (H1FY27), revenue grew 21% to ₹1,461 Crore, EBITDA was ₹315 Crore, and PAT rose 25% to ₹164 Crore. The company is on schedule with its expansion plans for CPVC and ECH, expected to commission within a quarter.